Amgen and AstraZeneca Report TEZSPIRE Eosinophilic Esophagitis Phase 3 CROSSING Results
TEZSPIRE Eosinophilic Esophagitis results from the Phase 3 CROSSING trial show histologic remission and dysphagia improvement at week 24, sustained through week 52, Amgen and AstraZeneca announced on October 20, 2026.
